Sugi Predict

Sugi Predict / Targets / IL2RA

IL2RA

Interleukin-2 receptor subunit alpha · P01589 · IL2RA on Sugi Atlas →

243 patent compounds predicted against IL2RA, 193 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6860593 SCHEMBL6860593 1.00 1/20
SCHEMBL6860596 SCHEMBL6860596 1.00 1/20
SCHEMBL14136720 SCHEMBL14136720 1.00 1/20
SCHEMBL14136732 SCHEMBL14136732 1.00 1/20
SCHEMBL15159838 SCHEMBL15159838 0.85 1/20
SCHEMBL4323684 SCHEMBL4323684 0.84 1/20
SCHEMBL4323694 SCHEMBL4323694 0.84 1/20
SCHEMBL4323700 SCHEMBL4323700 0.84 1/20
SCHEMBL4993522 SCHEMBL4993522 0.84 1/20
SCHEMBL12156024 SCHEMBL12156024 0.84 1/20
SCHEMBL15832297 SCHEMBL15832297 0.84 1/20
SCHEMBL30064536 SCHEMBL30064536 0.79 1/20
SCHEMBL15159835 SCHEMBL15159835 0.77 1/20
SCHEMBL19954949 SCHEMBL19954949 0.74 1/20
SCHEMBL6860600 SCHEMBL6860600 0.73 1/20
SCHEMBL14136733 SCHEMBL14136733 0.73 1/20
SCHEMBL20761277 SCHEMBL20761277 0.71 1/20
SCHEMBL30189895 SCHEMBL30189895 0.70 1/20
SCHEMBL20975833 SCHEMBL20975833 0.69 1/20
SCHEMBL13342153 SCHEMBL13342153 0.68 1/20

Clinical trials — most relevant to IL2RA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major PHASE4COMPLETED
Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease PHASE2/PHASE3UNKNOWN
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) PHASE1/PHASE2RECRUITING
Low Dose IL-2 for the Treatment of Crohn's Disease PHASE1/PHASE2RECRUITING
Anti-Tac for Treatment of Leukemia PHASE1/PHASE2COMPLETED
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients PHASE2UNKNOWN
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma PHASE2NOT_YET_RECRUITING
Efficacy of Interleukin-2 in Triple Negative Breast Cancer PHASE1/PHASE2NOT_YET_RECRUITING
RAPA-201 Therapy of Solid Tumors PHASE1/PHASE2RECRUITING
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector PHASE1/PHASE2COMPLETED
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) PHASE1/PHASE2RECRUITING
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC PHASE2RECRUITING
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma PHASE2COMPLETED
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant PHASE2COMPLETED
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus PHASE1/PHASE2WITHDRAWN
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases PHASE2COMPLETED
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer PHASE1COMPLETED
Low Dose IL-2 for Ulcerative Colitis PHASE1COMPLETED
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma PHASE1COMPLETED
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma PHASE1ACTIVE_NOT_RECRUITING
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) PHASE1NOT_YET_RECRUITING
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD) nanNOT_YET_RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty nanUNKNOWN
Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals nanUNKNOWN
Immunophenotypic Evaluation of IL-7R α in Acute Leukaemia nanUNKNOWN
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease nanAVAILABLE
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions nanRECRUITING
IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IL2RA binder may also engage these)

ProteinNameSimilarity
Q5MNY4 — 1.000 Q5MNY4 →
Q38IC8 — 1.000 Q38IC8 →
P01590 — 1.000 P01590 →
P41690 — 1.000 P41690 →
O62802 — 1.000 O62802 →
P26898 — 1.000 P26898 →
O02733 — 0.999 O02733 →
P26897 — 0.998 P26897 →
P12342 — 0.995 P12342 →
Q8R183 — 0.987 Q8R183 →
Q7TSA3 — 0.985 Q7TSA3 →
Q9D9J7 — 0.984 Q9D9J7 →
Q5RDA5 — 0.983 Q5RDA5 →
O95727 — 0.983 O95727 →
B2RTN2 — 0.983 B2RTN2 →
Q8K4B4 — 0.982 Q8K4B4 →
Q3U0X8 — 0.982 Q3U0X8 →
E7FEC4 — 0.982 E7FEC4 →
Q149L7 — 0.982 Q149L7 →
HAVCR2 Hepatitis A virus cellular receptor 2 0.982 landscape →
P43303 — 0.981 P43303 →
Q9HBV2 — 0.981 Q9HBV2 →
Q64314 — 0.981 Q64314 →
Q5FVR0 — 0.981 Q5FVR0 →
Q5BK49 — 0.981 Q5BK49 →
Q9GKE2 — 0.981 Q9GKE2 →
Q6QUN5 — 0.981 Q6QUN5 →
Q9Y279 — 0.981 Q9Y279 →
P0CAN6 — 0.981 P0CAN6 →
Q6AY06 — 0.981 Q6AY06 →